




Instance: composition-en-25b49674d9d703c70f7cbc179ed1a337
InstanceOf: CompositionUvEpi
Title: "Composition for parsabiv Package Leaflet"
Description:  "Composition for parsabiv Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp25b49674d9d703c70f7cbc179ed1a337)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - parsabiv"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Parsabiv is and what it is used for </li>
<li>What you need to know before you use Parsabiv </li>
<li>How to use Parsabiv </li>
<li>Possible side effects </li>
<li>How to store Parsabiv </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What parsabiv is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What parsabiv is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Parsabiv contains the active substance etelcalcetide, which reduces parathyroid hormone known as 
PTH. </p>
<p>Parsabiv is used to treat secondary hyperparathyroidism in patients with serious kidney disease who 
need haemodialysis to clear their blood of waste products. </p>
<p>In secondary hyperparathyroidism too much PTH is produced by the parathyroid glands (four small 
glands in the neck).  Secondary  means that the hyperparathyroidism is caused by another condition, 
e.g. kidney disease. Secondary hyperparathyroidism can cause the loss of calcium from the bones, 
which can lead to bone pain and fractures and problems with blood and heart vessels. By controlling 
the levels of PTH, Parsabiv helps to control calcium and phosphate in your body. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take parsabiv"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take parsabiv"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Parsabiv<br />
- if you are allergic to etelcalcetide or any of the other ingredients of this medicine (listed in 
section 6). 
- if you have very low levels of calcium in your blood. Your doctor will monitor your blood 
calcium levels. </p>
<p>Warnings and precautions 
Before you are given Parsabiv, tell your doctor if you have or have ever had: </p>
<p>heart problems, such as heart failure or arrhythmias (abnormal heart rhythm); </p>
<p>seizures (fits or convulsions). </p>
<p>Parsabiv reduces calcium levels. Please tell your doctor if you have spasms, twitches, or cramps in 
your muscles, or numbness or tingling in your fingers, toes or around your mouth or seizures, 
confusion or loss of consciousness while being treated with Parsabiv. For additional information see 
section 4. Low calcium levels can cause abnormal heart rhythm. Tell your doctor if you experience an unusually 
fast or pounding heartbeat, if you have heart rhythm problems or heart failure or if you take medicines 
that can cause heart rhythm problems, while receiving Parsabiv. For additional information see 
section 4. Very low levels of PTH over long periods can result in a type of abnormal bone structure known as 
adynamic bone which can only be diagnosed by biopsy. Your PTH levels will be monitored during 
treatment with Parsabiv and your dose of Parsabiv may be reduced if your PTH levels become very 
low. </p>
<p>Children and adolescents 
It is not known whether Parsabiv is safe and effective in children less than 18 years of age as it has not 
been studied in these patients. </p>
<p>Other medicines and Parsabiv 
Tell your doctor if you are taking, have recently taken or might take any other medicines, including 
those medicines obtained without a prescription, or any other medicines that lower serum calcium (e.g. 
cinacalcet and denosumab). </p>
<p>You should not receive Parsabiv together with cinacalcet. Tell your doctor if you are taking cinacalcet 
or have recently taken cinacalcet. </p>
<p>Pregnancy<br />
Parsabiv has not been tested in pregnant women. It is not known whether Parsabiv can harm your 
unborn baby. Tell your doctor if you are pregnant, think you may be pregnant, or plan to get pregnant 
when taking Parsabiv. As a precautionary measure, it is preferable to avoid the use of Parsabiv during 
pregnancy. </p>
<p>Breast-feeding 
It is not known whether Parsabiv can pass into breast milk. Tell your doctor if you are breast-feeding 
or plan to do so. Your doctor will then help you decide whether to stop breast-feeding, or whether to 
stop taking Parsabiv, considering the benefit of breast-feeding to the baby and the benefit of Parsabiv 
to the mother. </p>
<p>Driving and using machines 
Parsabiv has no or negligible influence on the ability to drive and use machines. However certain 
symptoms of low calcium levels (such as fits or convulsions) can affect your ability to drive or operate 
machinery. </p>
<p>Parsabiv contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially  sodium-
free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take parsabiv"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take parsabiv"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>The recommended starting dose for Parsabiv is 5 mg. It will be given by a doctor or nurse at the end of 
your haemodialysis treatment through the tube (bloodline) that connects you to the haemodialysis 
machine. Parsabiv will be given 3 times per week. The dose may be increased up to 15 mg or lowered 
down to 2.5 mg depending on your response. </p>
<p>You may need to take calcium and vitamin D supplements while being treated with Parsabiv. Your 
doctor will discuss this with you. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Low calcium levels in blood (hypocalcaemia) have been reported commonly (may affect up to 1 in people). If you feel numbness or tingling around your mouth or in your extremities, muscle aches or 
cramps and seizures (fits), you should tell your doctor immediately. These may be signs that your 
calcium levels are too low. </p>
<p>Very common: may affect more than 1 in 10 people </p>
<p>Nausea </p>
<p>Vomiting </p>
<p>Diarrhoea </p>
<p>Muscle spasms </p>
<p>Low calcium levels in blood with no symptoms </p>
<p>Common: may affect up to 1 in 10 people </p>
<p>High potassium levels in blood </p>
<p>Low phosphate levels in blood </p>
<p>Headache </p>
<p>Numbness or tingling sensation </p>
<p>Worsening heart failure </p>
<p>Disturbances in the heart s electrical activity seen as QT prolongation on electrocardiogram </p>
<p>Low blood pressure </p>
<p>Muscle pain </p>
<p>Uncommon: may affect up to 1 in 100 people </p>
<p>Seizures (fits or convulsions); for additional information see section 2 </p>
<p>Not known: frequency cannot be estimated from the available data </p>
<p>Allergic reactions (including anaphylactic reactions) </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store parsabiv"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store parsabiv"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date 
refers to the last day of that month. </p>
<p>Store in a refrigerator (2 C   8 C). 
Keep the vial in the outer carton in order to protect from light. </p>
<p>Once removed from the refrigerator: </p>
<p>Parsabiv is stable for a maximum of 7 cumulative days if stored in the original carton. No 
special temperature storage requirements are needed. </p>
<p>If removed from the original carton Parsabiv is stable for a maximum of 4 hours if protected 
from direct sunlight. </p>
<p>Do not use this medicine if you notice it has particles or it has changed colour. </p>
<p>For single use only. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Parsabiv contains 
- The active substance is etelcalcetide. 
Parsabiv 2.5 mg solution for injection: Each vial contains 2.5 mg of etelcalcetide in 0.5 mL 
solution (5 mg/mL). 
Parsabiv 5 mg solution for injection: Each vial contains 5 mg of etelcalcetide in 1 mL solution 
(5 mg/mL). 
Parsabiv 10 mg solution for injection: Each vial contains 10 mg of etelcalcetide in 2 mL 
solution (5 mg/mL). 
- The other ingredients are sodium chloride, succinic acid, water for injections, hydrochloric acid, 
and sodium hydroxide (refer to section 2: Parsabiv contains sodium). </p>
<p>What Parsabiv looks like and contents of the pack 
Parsabiv is a clear and colourless liquid. </p>
<p>Parsabiv is a solution for injection in a vial. </p>
<p>Pack sizes of 1, 6, 12 and 42 vials. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer 
Amgen Europe B.V. 
Minervum 74817 ZK Breda 
The Netherlands </p>
<p>Marketing Authorisation Holder 
Amgen Europe B.V. 
Minervum 74817 ZK Breda 
The Netherlands </p>
<p>Manufacturer 
Amgen NV 
Telecomlaan 5-7 
1831 Diegem 
Belgium </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
s.a. Amgen n.v. 
Tel/T l: +32 (0)2 7752Lietuva 
Amgen Switzerland AG Vilniaus filialas 
Tel: +370 5 219 7  </p>
<p>.: +359 (0)2 424 7Luxembourg/Luxemburg 
s.a. Amgen 
Belgique/Belgien 
Tel/T l: +32 (0)2 7752 esk  republika 
Amgen s.r.o. 
Tel: +420 221 773 Magyarorsz g 
Amgen Kft. 
Tel.: +36 1 35 44 Danmark 
Amgen, filial af Amgen AB, Sverige 
Tlf: +45 39617Malta 
Amgen B.V. 
The Netherlands 
Tel: +31 (0)76 5732Deutschland 
AMGEN GmbH 
Tel.: +49 89 1490Nederland 
Amgen B.V. 
Tel: +31 (0)76 5732Eesti 
Amgen Switzerland AG Vilniaus filialas 
Tel: +372 586 09Norge 
Amgen AB 
Tel: +47 23308<br />
Amgen      . . . 
 .: +30 210 3447 sterreich 
Amgen GmbH 
Tel: +43 (0)1 50 Espa a 
Amgen S.A. 
Tel: +34 93 600 18 Polska 
Amgen Biotechnologia Sp. z o.o. 
Tel.: +48 22 581 3France 
Amgen S.A.S. 
T l: +33 (0)9 69 363 Portugal 
Amgen Biofarmac utica, Lda. 
Tel: +351 21 4220Hrvatska 
Amgen d.o.o. 
Tel: +385 (0)1 562 57 Rom nia 
Amgen Rom nia SRL 
Tel: +4021 527 3Ireland 
Amgen Ireland Limited 
Tel: +353 1 8527Slovenija 
AMGEN zdravila d.o.o. 
Tel: +386 (0)1 585 1 sland 
Vistor hf. 
S mi: +354 535 7Slovensk  republika 
Amgen Slovakia s.r.o. 
Tel: +421 2 321 114 Italia 
Amgen S.r.l. 
Tel: +39 02 6241Suomi/Finland 
Amgen AB, sivuliike Suomessa/Amgen AB, filial 
i Finland 
Puh/Tel: +358 (0)9 54900K<br />
C.A. Papaellinas Ltd 
 .: +357 22741 Sverige 
Amgen AB 
Tel: +46 (0)8 6951Latvija 
Amgen Switzerland AG R gas fili le 
Tel: +371 257 25United Kingdom (Northern Ireland) 
Amgen Limited 
Tel: +44 (0)1223 420This leaflet was last revised in </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-25b49674d9d703c70f7cbc179ed1a337
InstanceOf: CompositionUvEpi
Title: "Composition for parsabiv Package Leaflet"
Description:  "Composition for parsabiv Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp25b49674d9d703c70f7cbc179ed1a337)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - parsabiv"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at bruge Parsabiv </li>
<li>Sådan skal du bruge Parsabiv </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What parsabiv is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What parsabiv is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Parsabiv indeholder det aktive stof etelcalcetid, der nedsætter mængden af et hormon, der dannes i 
biskjoldbruskkirtlerne og kaldes for PTH (paratyreoideahormon). </p>
<p>Parsabiv bruges til behandling af sekundær hyperparatyreoidisme hos patienter med alvorlig 
nyresygdom, der har behov for hæmodialyse for at rense blodet for affaldsstoffer. </p>
<p>Ved sekundær hyperparatyreoidisme producerer biskjoldbruskkirtlerne (fire små kirtler i halsen) for 
meget PTH. “Sekundær" betyder, at hyperparatyreoidismen skyldes en anden tilstand, for eksempel 
nyresygdom. Sekundær hyperparatyreoidisme kan medføre tab af calcium (kalk) fra knoglerne, som 
kan medføre knoglesmerter og knoglebrud samt problemer med blod- og hjertekar. Parsabiv regulerer 
indholdet af PTH i blodet og er på den måde med til at regulere indholdet af calcium og fosfat i 
kroppen. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take parsabiv"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take parsabiv"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Parsabiv<br />
- hvis du er allergisk over for etelcalcetid eller et af de øvrige indholdsstoffer i Parsabiv (angivet i 
afsnit 6). 
- hvis du har meget lavt indhold af calcium i blodet. Din læge vil løbende kontrollere indholdet af 
calcium i dit blod. </p>
<p>Advarsler og forsigtighedsregler 
Fortæl det til din læge, inden du får Parsabiv, hvis du har eller nogensinde har haft: 
 
problemer med hjertet, for eksempel hjertesvigt eller unormal hjerterytme (arytmier), 
 
krampeanfald. </p>
<p>Parsabiv nedsætter indholdet af calcium i blodet. Fortæl det til din læge, hvis du får spasmer, 
muskelspjæt eller kramper i dine muskler eller følelsesløshed eller prikken i dine fingre eller tæer eller 
omkring munden, eller hvis du får krampeanfald, bliver forvirret eller mister bevidstheden, mens du er 
i behandling med Parsabiv. Afsnit 4 indeholder mere information. </p>
<p>Lavt calciumniveau kan forårsage unormal hjerterytme. Fortæl det til din læge, hvis du mærker en 
usædvanligt hurtig eller bankende hjerterytme (puls), mens du er i behandling med Parsabiv, eller hvis 
du har problemer med hjerterytmen eller har haft hjertesvigt, eller hvis du får medicin, som kan give 
problemer med hjerterytmen. Afsnit 4 indeholder mere information. </p>
<p>Hvis man har et meget lavt PTH-niveau i lang tid, kan det medføre en unormal knoglestruktur, der 
kaldes for adynamisk knogle, og som kun kan diagnosticeres med en vævsprøve (biopsi). Dit 
PTH-niveau vil blive kontrolleret under behandlingen med Parsabiv, og din dosis af Parsabiv vil 
muligvis blive reduceret, hvis dit PTH-niveau bliver meget lavt. </p>
<p>Børn og unge 
Det vides ikke, om Parsabiv er sikkert og effektivt at bruge til børn under 18 år, da det ikke er 
undersøgt hos disse patienter. </p>
<p>Brug af anden medicin sammen med Parsabiv 
Fortæl det altid til lægen, hvis du tager anden medicin, for nylig har taget anden medicin eller 
planlægger at tage anden medicin. Det gælder også medicin, som ikke er købt på recept eller anden 
medicin, som sænker indholdet af calcium i blodet (f.eks. cinacalcet og denosumab). </p>
<p>Du må ikke få Parsabiv sammen med cinacalcet. Fortæl det til lægen, hvis du tager cinacalcet eller har 
gjort det for nylig. </p>
<p>Graviditet 
Parsabiv er ikke blevet afprøvet på gravide kvinder. Det vides ikke, om Parsabiv kan skade et ufødt 
barn. Hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du 
fortælle det til din læge, før du bruger Parsabiv. Som en sikkerhedsforanstaltning bør brug af Parsabiv 
undgås under graviditeten. </p>
<p>Amning 
Det vides ikke, om Parsabiv kan blive udskilt i mælken hos mennesker. Fortæl det til din læge, hvis du 
ammer eller planlægger at amme. Din læge vil kunne hjælpe dig med at finde ud af, om du skal holde 
op med at amme eller holde op med at bruge Parsabiv under hensyntagen til fordelen ved at amme 
barnet og din fordel ved at bruge Parsabiv. </p>
<p>Trafik- og arbejdssikkerhed 
Parsabiv påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner. 
Visse symptomer på lavt calciumniveau (for eksempel kramper) kan dog påvirke evnen til at køre 
motorkøretøj og betjene maskiner. </p>
<p>Parsabiv indeholder natrium 
Denne medicin indeholder mindre end 1 mmol natrium (23 mg) pr. hætteglas, dvs. den er i det 
væsentlige natriumfri. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take parsabiv"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take parsabiv"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Den anbefalede startdosis af Parsabiv er 5 mg. Det vil blive givet af en læge eller sygeplejerske i 
afslutningen af din hæmodialyse gennem det rør (blodslange), der forbinder dig til dialysemaskinen. 
Du vil få Parsabiv 3 gange om ugen. Dosis kan øges til op til 15 mg eller nedsættes til 2,5 mg 
afhængigt af, hvordan du reagererpå behandlingen. </p>
<p>Du vil muligvis få behov for tilskud af calcium og vitamin D, mens du er i behandling med Parsabiv. 
Din læge vil fortælle dig mere om dette. </p>
<p>Er du i tvivl, så spørg lægen eller sygeplejersken. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Lave calciumniveauer i blodet (hypokalcæmi) er rapporteret med hyppigheden almindelig (kan ramme 
op til 1 ud af 10 personer). Fortæl det straks til din læge, hvis du mærker følelsesløshed eller prikken 
omkring munden eller i arme og ben, eller hvis du får muskelsmerter eller muskelkramper og 
krampeanfald. Det kan være tegn på, at dit calciumniveau er for lavt. </p>
<p>Meget almindelig: kan ramme flere end 1 ud af 10 personer 
 
Kvalme 
 
Opkastning 
 
Diaré 
 
Muskelspasmer 
 
Lavt calciumniveau i blodet uden nogen symptomer </p>
<p>Almindelige: kan ramme op til 1 ud af 10 personer 
 </p>
<p> 
Højt kaliumniveau i blodet 
 
Lavt fosfatniveau i blodet 
 
Hovedpine 
 
Følelsesløshed eller prikkende fornemmelse 
 
Forværring af hjertesvigt 
 
Forstyrrelser i hjertets elektriske aktivitet, der ses som QT-forlængelse i et elektrokardiogram 
 
Lavt blodtryk 
 
Muskelsmerter </p>
<p>Ikke almindelig: kan ramme op til 1 ud af 100 personer 
 
Krampeanfald; afsnit 2 indeholder mere information </p>
<p>Ikke kendt: kan ikke estimeres ud fra forhåndenværende data 
 
Allergiske reaktioner (inklusive anafylaktiske reaktioner) </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller sygeplejersken. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store parsabiv"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store parsabiv"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken efter EXP. Udløbsdatoen er den sidste 
dag i den nævnte måned. </p>
<p>Opbevares i køleskab (2 °C - 8 °C). 
Opbevar hætteglasset i den ydre karton for at beskytte mod lys. </p>
<p>Efter at lægemidlet er taget ud af køleskabet: 
 
Parsabiv er stabilt i maksimalt 7 dage i træk, når det opbevares i den originale karton. Der er 
ingen særlige krav vedrørende opbevaringstemperaturer. 
 
Når Parsabiv er taget ud af den originale karton, er det stabilt i maksimalt 4 timer, hvis det er 
beskyttet mod direkte sollys. </p>
<p>Brug ikke lægemidlet, hvis du kan se, at det indeholder partikler eller har skiftet farve. </p>
<p>Kun til engangsbrug. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Parsabiv indeholder:</p>
<ul>
<li>Aktivt stof: etelcalcetid. 
Parsabiv 2,5 mg injektionsvæske, opløsning: Hvert hætteglas indeholder 2,5 mg etelcalcetid i 
0,5 ml opløsning (5 mg/ml). 
Parsabiv 5 mg injektionsvæske, opløsning: Hvert hætteglas indeholder 5 mg etelcalcetid i 1 ml 
opløsning (5 mg/ml). 
Parsabiv 10 mg injektionsvæske, opløsning: Hvert hætteglas indeholder 10 mg etelcalcetid i 
2 ml opløsning (5 mg/ml). </li>
<li>Øvrige indholdsstoffer: natriumchlorid, ravsyre, vand til injektionsvæsker, saltsyre og 
natriumhydroxid (se afsnit 2: Parsabiv indeholder natrium). </li>
</ul>
<p>Udseende og pakningsstørrelser 
Parsabiv er en klar og farveløs væske. </p>
<p>Parsabiv er en injektionsvæske i et hætteglas. </p>
<p>Pakningsstørrelser med 1, 6, 12 og 42 hætteglas. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller 
Amgen Europe B.V. 
Minervum 74817 ZK Breda 
Holland </p>
<p>Indehaver af markedsføringstilladelsen 
Amgen Europe B.V. 
Minervum 74817 ZK Breda 
Holland </p>
<p>Fremstiller 
Amgen NV 
Telecomlaan 5-7 
1831 Diegem 
Belgien </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
s.a. Amgen n.v. 
Tel/Tél: +32 (0)2 7752 
Lietuva 
Amgen Switzerland AG Vilniaus filialas 
Tel: +370 5 219 7 
България 
Амджен България ЕООД 
Тел.: +359 (0)2 424 7 
Luxembourg/Luxemburg 
s.a. Amgen 
Belgique/Belgien 
Tel/Tél: +32 (0)2 7752Česká republika 
Amgen s.r.o. 
Tel: +420 221 773<br />
Magyarország 
Amgen Kft. 
Tel.: +36 1 35 44<br />
Danmark 
Amgen, filial af Amgen AB, Sverige 
Tlf: +45 39617 
Malta 
Amgen B.V. 
The Netherlands 
Tel: +31 (0)76 5732Deutschland 
AMGEN GmbH 
Tel.: +49 89 1490 
Nederland 
Amgen B.V. 
Tel: +31 (0)76 5732Eesti 
Amgen Switzerland AG Vilniaus filialas 
Tel: +372 586 09 
Norge 
Amgen AB 
Tel: +47 23308Ελλάδα 
Amgen Ελλάς Φαρμακευτικά Ε.Π.Ε. 
Τηλ.: +30 210 3447 
Österreich 
Amgen GmbH 
Tel: +43 (0)1 50 España 
Amgen S.A. 
Tel: +34 93 600 18<br />
Polska 
Amgen Biotechnologia Sp. z o.o. 
Tel.: +48 22 581 3 
France 
Amgen S.A.S. 
Tél: +33 (0)9 69 363<br />
Portugal 
Amgen Biofarmacêutica, Lda. 
Tel: +351 21 4220 
Hrvatska 
Amgen d.o.o. 
Tel: +385 (0)1 562 57<br />
România 
Amgen România SRL 
Tel: +4021 527 3 
Ireland 
Amgen Ireland Limited 
Tel: +353 1 8527 
Slovenija 
AMGEN zdravila d.o.o. 
Tel: +386 (0)1 585 1 
Ísland 
Vistor hf. 
Sími: +354 535 7 
Slovenská republika 
Amgen Slovakia s.r.o. 
Tel: +421 2 321 114<br />
Italia 
Amgen S.r.l. 
Tel: +39 02 6241 
Suomi/Finland 
Amgen AB, sivuliike Suomessa/Amgen AB, filial 
i Finland 
Puh/Tel: +358 (0)9 54900 
Kύπρος 
C.A. Papaellinas Ltd 
Τηλ.: +357 22741<br />
Sverige 
Amgen AB 
Tel: +46 (0)8 6951 
Latvija 
Amgen Switzerland AG Rīgas filiāle 
Tel: +371 257 25 
United Kingdom (Northern Ireland) 
Amgen Limited 
Tel: +44 (0)1223 420 </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu og på Lægemiddelstyrelsens hjemmeside 
http://www.laegemiddelstyrelsen.dk </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-25b49674d9d703c70f7cbc179ed1a337
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for parsabiv Package Leaflet for language en"
Description: "ePI document Bundle for parsabiv Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-25b49674d9d703c70f7cbc179ed1a337"
* entry[0].resource = composition-en-25b49674d9d703c70f7cbc179ed1a337

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp25b49674d9d703c70f7cbc179ed1a337"
* entry[=].resource = mp25b49674d9d703c70f7cbc179ed1a337
                            
                    
Instance: bundlepackageleaflet-da-25b49674d9d703c70f7cbc179ed1a337
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for parsabiv Package Leaflet for language da"
Description: "ePI document Bundle for parsabiv Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-25b49674d9d703c70f7cbc179ed1a337"
* entry[0].resource = composition-da-25b49674d9d703c70f7cbc179ed1a337

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp25b49674d9d703c70f7cbc179ed1a337"
* entry[=].resource = mp25b49674d9d703c70f7cbc179ed1a337
                            
                    



Instance: mp25b49674d9d703c70f7cbc179ed1a337
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Parsabiv 2.5 mg solution for injection"
Description: "Parsabiv 2.5 mg solution for injection"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "Parsabiv 2.5 mg solution for injection"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Parsabiv 2.5 mg solution for injection"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 25b49674d9d703c70f7cbc179ed1a337ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "parsabiv"

* status = #current
* mode = #working

* title = "List of all ePIs associated with parsabiv"

* subject = Reference(mp25b49674d9d703c70f7cbc179ed1a337)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#parsabiv "parsabiv"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-25b49674d9d703c70f7cbc179ed1a337) // parsabiv en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-25b49674d9d703c70f7cbc179ed1a337) // parsabiv da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-25b49674d9d703c70f7cbc179ed1a337
InstanceOf: List

* insert 25b49674d9d703c70f7cbc179ed1a337ListRuleset
    